WoundSource Page Designs_White Papers small

Caring for Wounds: The Clinical Benefits of Extracorporeal Shock Wave Therapy

The Clinical Benefits of Extracorporeal Schock Wave Therapy
 
By submitting your information through this form, you confirm that you agree to WoundSource's Privacy Policy , as well as sharing your information with any partners for marketing purposes. You can opt out at any time.
 

Management of chronic wounds is challenging across all care settings and also incurs high costs for both patients and health care systems. Extracorporeal shock wave therapy (ESWT) has the potential to decrease costs associated with treatment of diabetic foot ulcers, second-degree burns, and other complex wounds by shortening healing time.

This white paper on ESWT is sponsored by SoftWave Tissue Regeneration Technologies, the makers of SoftWave DermaGold 100. The guide describes the mechanism of action and classification of ESWT and the indications for use of this therapy, as well as providing an overview of diabetic foot ulcers, second-degree burns, and traumatic and surgical wounds.

This guide is a useful resource for wound care professionals who want to know more about ESWT, a non-invasive approach to optimal results in their patients with chronic wounds. It covers the following topics, among others:

This white paper contains information on the following topics:

Epidemiology of chronic wounds
ESWT properties and uses in wound care
Diabetic foot ulcers and other injuries treatable by ESWT
ESWT case studies
Research studies supporting ESWT
Properties and benefits of DermaGold 100 ESWT

This paper is written for wound care clinicians and purchasing directors with an interest in product solutions. This paper was developed by an independent third party.

Sponsored by SoftWave Tissue Regeneration Technologies.

Management of chronic wounds is challenging across all care settings and also incurs high costs for both patients and health care systems. Extracorporeal shock wave therapy (ESWT) has the potential to decrease costs associated with treatment of diabetic foot ulcers, second-degree burns, and other complex wounds by shortening healing time.

This white paper on ESWT is sponsored by Tissue Regeneration Technologies (MTS Medical), the makers of SoftWave DermaGold 100. The guide describes the mechanism of action and classification of ESWT and the indications for use of this therapy, as well as providing an overview of diabetic foot ulcers, second-degree burns, and traumatic and surgical wounds.

This guide is a useful resource for wound care professionals who want to know more about ESWT, a non-invasive approach to optimal results in their patients with chronic wounds. It covers the following topics, among others:

This white paper contains information on the following topics:

Costs of complex and chronic wounds
ESWT properties and uses in wound care
Diabetic foot ulcers and other injuries treatable by ESWT
ESWT case studies
Research studies supporting ESWT
Properties and benefits of DermaGold 100 ESWT

This paper is written for wound care clinicians and purchasing directors with an interest in product solutions. This paper was developed by an independent third party.

Sponsored by SoftWave Tissue Regeneration Technologies.

WoundSource
The World’s Definitive Source for Wound Care & Product Information